8-pCPT-conjugated cyclic AMP analogs exert thromboxane receptor antagonistic properties

Thrombosis and Haemostasis

Volumn 103, Issue 3, 2010, Pages 662-676

  Sand, Carsten ^a   Grandoch, Maria ^a   Börgermann, Christof ^a   Oude Weernink, Paschal A ^a   Mahlke, Yvonne ^a   Schwindenhammer, Benjamin ^a   Weber, Artur Aron ^a   Fischer, Jens W ^a   Jakobs, Karl H ^a   Schmidt, Martina ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Endothelial cells; Exchange protein directly activated by cyclic AMP; Human platelets; Thromboxane A2; Vascular tissue

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 8 (4 CHLOROPHENYLTHIO) 2' O METHYL CYCLIC ADENOSINE MONOPHOSPHATE; CYCLIC AMP DERIVATIVE; INTERCELLULAR ADHESION MOLECULE 1; NORADRENALIN; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CORONARY ARTERY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR RING;

ANIMALS; AORTA; CELL ADHESION MOLECULES; CELL MOVEMENT; CORONARY VESSELS; CYCLIC AMP; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; PLATELET AGGREGATION; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE; VASOCONSTRICTION;

EID: 77749254922     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-06-0341     Document Type: Article

References (73)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century. Nat Rev Drug Discovery 2002; 1: 309-315.
2. Zambon AC, Zhang L, Minovitsky S, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA 2005; 102: 8561-8566.
3. Bos JL. Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 2003; 4: 733-738.
4. Roscioni SS, Elzinga CRS, Schmidt M. Epac: effectors and biological functions. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 345-357.
5. Borland G, Smith BO, Yarwood SJ. Epac proteins transduce diverse cellular actions of cAMP. Brit J Pharmacol 2009; 158: 70-86.
6. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Brit J Pharmacol 2009; preub online doi:10.1111/j.1476-5381.2009.00458:
7. Schmidt M, Sand C, Jakobs KH, et al. Epac and the cardiovascular system. Curr Opin Pharmacol 2007; 7: 193-200.
8. Schmidt M, Evellin S, Oude Weernink PA, et al. A new phospholipase-C- calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nature Cell Biol 2001; 3: 1020-1024.
9. Oestreich EA, Wang H, Malik S, et al. Epac-mediated activation of phospholipase C(epsilon) plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes. J Biol Chem 2007; 282: 5488-5495.
10. Oestreich EA, Malik S, Goonasekera SA, et al. Epac and phospholipase Cε regulate Ca2+ release in the heart by activation of protein kinase Cε and calcium-calmodulin kinase II. J Biol Chem 2009; 284: 1514-1522.
11. Pereira L, Métrich M, Fernández-Velasco M, et al. The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytes. J Physiol 2007; 583.2: 685-694.
12. Métrich M, Morel E, Berthouze M, et al. Functional characterization of the cAMP-binding proteins Epac in cardiac myocytes. Pharmacolog Rep 2009; 61: 146-153.
13. Cazorla O, Lucas A, Poirier F, et al. The cAMP binding protein Epac regulates cardiac myofilament function. Proc Natl Acad Sci USA 2009; 106: 14144-14149.
14. Ster J, De Bock F, Guerineau NC, et al. Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent K+ channels in cerebellar neurons. Proc Natl Acad Sci USA 2007; 104: 2519-2524.
15. Aromataris EC, Roberts ML, Barritt GJ, et al. Glucagon activates Ca2+ and Cl-channels in rat hepatocytes. J Physiol 2006; 573: 611-625.
16. Purves GI, Kamishima T, Davies LM, et al. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive potassium channels. J Physiol 2009; 587: 3639-3650.
17. Morel E, Marcantoni A, Gastineau M, et al. cAMP-binding protein Epac induces cardiomyocytes hypertrophy. Circ Res 2005; 97: 1296-1304.
18. Métrich M, Lucas A, Gastineau M, et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 2008; 102: 959-965.
19. Wang H, Oestreich EA, Maekawa N, et al. Phospholipase Cε modulates β-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res 2005; 97: 1305-1313.
20. Ulucan C, Wang X, Baljinnyam E, et al. Developmental changes in gene expression of Epac and its upregulation in myocardial hypertrophy. Am J Physiol Heart Circ Physiol 2007; 293: H1662-H1672.
21. Komatsu M, Ruoslathi E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 2005; 11: 1346-1350.
22. Yokoyama U, Minamisawa S, Quan H, et al. Epac1 is upregulated during neointima formation and promotes vascular smooth muscle migration. Am J Physiol Heart Circ Physiol 2008; 295: H1547-H1555.
23. Yokoyama U, Minamisawa S, Quan H, et al. PGE2-activate EPAC promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of PKA. J Biol Chem 2008; 283: 28702-28709.
24. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol 2005; 25: 136-146.
25. Cullere X, Shaw SK, Andersson L, et al. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPases. Blood 2005; 105: 1950-1955.
26. Sehrawat S, Cullere X, Patel S, et al. Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function. Mol Biol Cell 2008; 19: 1261-1270.
27. Birukova AA, Zagranichnaya T, Fu P, et al. Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell Res 2007; 313: 2504-2520.
28. Birukova AA, Zagranichnaya T, Alekseeva E, et al. Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J Cell Physiol 2008; 215: 715-724.
29. Lorenowicz MJ, Fernandez-Borja M, van Stalborch A-MD, et al. Microtubule dynamics and Rac-1 signaling independently regulate barrier function in lung epithelial cells. Am J Respir Cell Mol Biol 2007; 293: L1321-L1331.
30. Wittchen ES, Worthylake RA, Kelly P, et al. Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function. J Biol Chem 2005; 280: 11675-11682.
31. Basoni C, Nobles M, Grimshaw A, et al. Inhibitory control of TGF-β1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes. FASEB J 2005; 19: 822-824.
32. Netherton SJ, Sutton JA, Wilson LS, et al. Both protein kinase A and exhcange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. Circ Res 2007; 101: 768-776.
33. Lorenowicz MJ, Fernandez-Borja M, Kooistra MRH, et al. PKA and Epac1 regulate endothelial integrity and migration though parallel and independent pathways. Eur J CellBiol 2008; 87: 779-792.
34. Carmona G, Chavakis E, Koehl U, et al. Activation of Epac stimulates integrind-dependent homing of progenitor cells. Blood 2008; 111: 2640-2646.
35. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 2008; 19: 192-198.
36. Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004; 5: 959-970.
37. Di Benedetto G, Zoccarato A, Lissandron V, et al. Protein kinase A Type I and II define distinct intracellular signaling compartments. Circ Res 2008; 103: 836-844.
38. Dodge-Kafka KLSJ, Pare GC, Michel JJC, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005; 437: 574-578.
39. Nijholt IM, Dolga AM, Ostroveanu A, et al. Neuronal AKAP150 coordinates PKA and Epac mediated PKB/Akt phosphorylation. Cell Signal 2008; 20: 1715-1724.
40. Enserink JM, Christensen AE, de Rooji J, et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 2002; 4: 901-906.
41. Christensen AE, Selheim F, de Rooji J, et al. cAMP analog mapping of Epac 1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 2003; 278: 35394-35402.
42. Holz GG, Kang G, Harbeck M, et al. Cell physiology of cAMP sensor Epac. J Physiol 2006; 577: 5-15.
43. Holz GG, Chepurny OG, Schwede F. Epac-selelctive cAMP analogs: New tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. Cell Signal 2008; 20: 10-20.
44. Sukhanova IF, Kozhevnikova LM, Popov EG, et al. Activators of Epac proteins induce relaxation of isolated rat aorta. Dokl Biol Sci 2006; 411: 441-444.
45. Laxman S, Riechers A, Sadilek M, et al. Hydrolysis products of cAMP analogs cause transformation of Trypanosoma brucei from slender to stumpy-like forms. Proc Natl Acad Sci USA 2006; 103: 19194-19199.
46. Poppe H, Rybalkin SD, Rehmann H, et al. Cyclic nucleotide analogs as probes of signaling pathways. Nat Methods 2008; 5: 277-278.
47. Enyeart JA, Enyeart JJ. Metabolites of an Epac-selective cAMP anlog induce cortisol synthesis by adrenocortical cells through a cAMP-independent pathway. Plos One 2009; 4: e6088
48. Li Q, Zhang L, Pfaffendorf M, et al. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Brit J Pharmacol 1995; 116: 2963-2970.
49. Altmann C, Meyer zu Heringdorf D, Böyükbas D, et al. Sphingosylphosphorylcholine, a naturally occuring lipid mediator, inhibits human platelet function. Brit J Pharmacol 2003; 138: 435-444.
50. Marwali MR, Hu C-P, Mohandas B, et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: Role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther 2007; 322: 1324-1332.
51. López de Jesús M, Stope MB, Oude Weernink PA, et al. Cyclic AMP-dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to phospholipase D stimulation. J Biol Chem 2006; 281: 21837-21847.
52. Keiper M, Stope MB, Szatkowski D, et al. Epac- and Ca2+ -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J Biol Chem 2004; 279: 46497-46508.
53. Kooistra MRH, Corada M, Dejana E, et al. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 2005; 579: 4966-4972.
54. Hermann A, Schrör K, Weber A-A. CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. Eur J CellBiol 2002; 81: 213-221.
55. Grandoch M, Rose A, ter Braak M, et al. Epac inhibits migration and proliferation of human prostate carcinoma cells. Brit J Cancer 2009; in press:
56. Gräbner R, Till U, Heller R. Flow cytometric determination of E-selectin, vascular cell adhesion molecule-1, and intercellular cell adhesion molecule-1 in formaldehyde-fixed endothelial cell monolayers. Cytometry 2000; 40: 238-244.
57. Herr W, Ranieri E, Olson W, et al. Mature dendritic cells pulsed wih freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD(+) T lymphocytes. Blood 2000; 96: 1857-1864.
58. Takayasu-Okishio M, Terashita Z, Kondo K. Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosytnhesis in rat vascular smooth muscle cells. Biochem Pharmacol 1990; 40: 2713-2717.
59. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 58-178.
60. Torti M, Lapetina EG. Structure and function of rap proteins in human platelets. Thromb Haemost 1994; 71: 533-543.
61. Franke B, Akkerman J-W, Bos JL. Rapid Ca2+-mediated activation of Rap1 in human platelets. EMBO J 1997; 16: 252-259.
62. Lorenowicz MJ, van Gils J, de Boer M, et al. Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis. J Leukoc Biol 2006; 80: 1542-1552.
63. Smolenski A, Bachmann C, Reinhard K, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serin 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998; 273: 20029-20035.
64. Ishizuka T, Suzuki K, Kawakami M, et al. Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stumlated vascular endothelial cells. Eur J Pharmacol 1996; 312: 367-377.
65. Ishizuka T, Kawakami M, Matsuki Y, et al. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol 1998; 112: 464-470.
66. Lu Y-T, Chen P-G, Liu SF. Time course of lung ischemia-reperfusion- induced ICAM-1 expression and its role in ischemia-reperfusion lung injury. J Appl Physiol 2002; 93: 620-628.
67. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61: 22-32.
68. Soyka R, Guth BD, Weisenberger HM et al. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J Med Chem 1999; 42: 1235-1249.
69. Swayne GT, Maguire J, Dolan J, et al. Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists. Eur J Pharmacol 1988; 152: 311-319.
70. Cimetière B, Dubuffet T, Landras C, et al. New tetrahydronapthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. Biorgan Med Chem Lett 1998; 8: 1381-1396.
71. Hall RA, Gillard J, Guindon Y, et al. Pharmacology of L-655,240 (3-[1-(4-chlrobenzyl)-5-fluoro-3-methyl-indol-2yl]2,2-dimethylpropanoiacid); a potent, selective thromboxane/prostaglandine endoperoxide antagonist. Eur J Pharmacol 1987; 135: 193-201.
72. Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pigs smooth muscles. J Pharmacol Exp Ther 1992; 260: 789-794.
73. Dao KK, Teigen K, Kopperud R, et al. Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. J Biol Chem 2006; 281: 21500-21511.